trump executive order on glp 1 unveils deal to expand coverage and lower costs obesity drugs – NewsNation Trump announces deal to sell
Description
Incretin mimetics considerably expanded their proven benefits beyond obesity in 2024
The excess risk of acute pancreatitis was more pronounced during the early phase of follow-up (first 6 months)
Originally developed for diabetes, these drugs are now popular for weight loss, especially following expanded approval for adolescents.
Learn how diabetic meds for weight loss work and who they're for
Equip fitness pros to support clients on GLP-1 meds like Ozempic
While this large retrospective study cannot fully prove causality, it provides robust real-world evidence that supports the safety of these medications
